Bladder Cancer Studies Currently Recruiting Participants at the University of Chicago Medicine Comprehensive Cancer Center

Study Number Title
15550B Bladder Cancer Sample Collection
Select
09-288-B Identification of genetic determinants of response to neoadjuvant cisplatin-based chemotherapy in urothelial cancer
12278A Clinical Urology Research Screening Protocol
Select
11-0646 S1011: A Phase III Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radial Cystectomy for Muscle Invasive Urothelial Cancer
Select
IRB14-0894 A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors
Select
IRB14-0081 Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
Select
IRB13-0416 An Integrated Phase II/III, Open Label, Randomized, Parallel and Controlled Study of the Safety and Efficacy of CG0070 Oncolytic Vector Regimen in Patients with Non-Muscle Invasive Bladder Carcinoma In Situ Disease (NMIBCis, meaning cis and cis with TA and/or T1) and Who Have Failed BCG Therapy and Refused Cystectomy.
Select
IRB14-1429 A Phase 1 Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Tremelimumab (Anti-CTLA-4 Antibody) in Subjects with Advanced Solid Tumor
Select
IRB14-0105 A Phase I, Open-Label, Dose Escalation Study of MGA271 (Fc-optimized Humanized Anti-B7-H3 Monoclonal Antibody) in Patients with Refractory B7-H3-Expressing Neoplasms or Neoplasms whose Vasculature Expresses B7-H3
Select
IRB15-0322 An Open-Label, Single-Arm, Phase 2 Study of Moncetinostat in Selected Patients with Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Select
IRB15-0330 A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) in combination with Bevacizumab Versus Sunitinib in Untreated Advanced Renal Cell Carcinoma
Select
IRB14-1040 Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer
Select
CIRB14-1105 S1314: A Randomized Phase II Study of Co-eXpression ExtrapolatioN (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Select
IRB13-1410 A Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT) and Received Prior Treatment with Induction Bacille Calmette-Guerin (BCG) (Sponsor ID HS410-101)
Select
IRB14-1229 A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Advanced/Unresectable or Metastatic Urothelial Cancer

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.
Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT team